

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Cardiovascular Advisory Committee provisional recommendations 27 June 2025

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Empagliflozin for the treatment of chronic heart failure with mildly reduced or preserved ejection fraction, for people with NYHA class II-IV, within the context of cardiovascular disease, subject to eligibility criteria	High Priority

[More information about the Cardiovascular Advisory Committee is on Pharmac's website](#)

Released 7 August 2025